CN100446773C - 复方痤疮微乳膏及制备方法 - Google Patents
复方痤疮微乳膏及制备方法 Download PDFInfo
- Publication number
- CN100446773C CN100446773C CNB2006100440011A CN200610044001A CN100446773C CN 100446773 C CN100446773 C CN 100446773C CN B2006100440011 A CNB2006100440011 A CN B2006100440011A CN 200610044001 A CN200610044001 A CN 200610044001A CN 100446773 C CN100446773 C CN 100446773C
- Authority
- CN
- China
- Prior art keywords
- component
- cream
- spironolactone
- azithromycin
- stir
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 208000002874 Acne Vulgaris Diseases 0.000 title claims abstract description 26
- 206010000496 acne Diseases 0.000 title claims abstract description 26
- 239000006071 cream Substances 0.000 title claims abstract description 20
- 150000001875 compounds Chemical class 0.000 title claims abstract description 11
- 238000002360 preparation method Methods 0.000 title description 9
- 239000003814 drug Substances 0.000 claims abstract description 49
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 28
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 20
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims abstract description 20
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims abstract description 18
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims abstract description 12
- 235000021355 Stearic acid Nutrition 0.000 claims abstract description 11
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims abstract description 11
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims abstract description 11
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims abstract description 11
- 239000008117 stearic acid Substances 0.000 claims abstract description 11
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229960004099 azithromycin Drugs 0.000 claims abstract description 10
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 claims abstract description 10
- 229960002256 spironolactone Drugs 0.000 claims abstract description 10
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims abstract description 9
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 claims abstract description 9
- 229940075507 glyceryl monostearate Drugs 0.000 claims abstract description 9
- 229940057995 liquid paraffin Drugs 0.000 claims abstract description 9
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims abstract description 9
- 230000001476 alcoholic effect Effects 0.000 claims abstract description 8
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000008213 purified water Substances 0.000 claims abstract description 8
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims abstract description 7
- 235000019437 butane-1,3-diol Nutrition 0.000 claims abstract description 6
- 239000004530 micro-emulsion Substances 0.000 claims description 19
- 238000003756 stirring Methods 0.000 claims description 19
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 18
- 229960001727 tretinoin Drugs 0.000 claims description 9
- 238000001816 cooling Methods 0.000 claims description 8
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims description 7
- 239000013521 mastic Substances 0.000 claims description 7
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 claims description 7
- 238000007872 degassing Methods 0.000 claims description 6
- 230000001804 emulsifying effect Effects 0.000 claims description 6
- 239000000839 emulsion Substances 0.000 claims description 6
- 239000012467 final product Substances 0.000 claims description 6
- 238000009413 insulation Methods 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 238000004321 preservation Methods 0.000 claims description 6
- 229940058015 1,3-butylene glycol Drugs 0.000 claims description 5
- FVDRFBGMOWJEOR-UHFFFAOYSA-N hexadecan-2-ol Chemical compound CCCCCCCCCCCCCCC(C)O FVDRFBGMOWJEOR-UHFFFAOYSA-N 0.000 claims description 4
- 239000000463 material Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 31
- 239000002245 particle Substances 0.000 abstract description 12
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 abstract description 5
- 239000000203 mixture Substances 0.000 abstract description 4
- 230000001681 protective effect Effects 0.000 abstract description 3
- 230000035515 penetration Effects 0.000 abstract description 2
- YPFDHNVEDLHUCE-UHFFFAOYSA-N propane-1,3-diol Chemical compound OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 abstract 2
- 229930002330 retinoic acid Natural products 0.000 abstract 2
- 230000000295 complement effect Effects 0.000 abstract 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 abstract 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 abstract 1
- 229940043351 ethyl-p-hydroxybenzoate Drugs 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 235000011187 glycerol Nutrition 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
- 239000012071 phase Substances 0.000 description 11
- 239000000243 solution Substances 0.000 description 7
- 210000003491 skin Anatomy 0.000 description 6
- 206010011732 Cyst Diseases 0.000 description 5
- 208000031513 cyst Diseases 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 4
- 210000004209 hair Anatomy 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 230000009471 action Effects 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000003780 hair follicle Anatomy 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000344 soap Substances 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 230000000149 penetrating effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 210000001732 sebaceous gland Anatomy 0.000 description 2
- 206010040882 skin lesion Diseases 0.000 description 2
- 231100000444 skin lesion Toxicity 0.000 description 2
- 210000003859 smegma Anatomy 0.000 description 2
- 241000186427 Cutibacterium acnes Species 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 101100516304 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) nuo-21 gene Proteins 0.000 description 1
- 241000531763 Otididae Species 0.000 description 1
- 241001404789 Smilax glabra Species 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000007957 coemulsifier Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004880 lymph fluid Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229940055019 propionibacterium acne Drugs 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000036561 sun exposure Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
Abstract
Description
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2006100440011A CN100446773C (zh) | 2006-04-29 | 2006-04-29 | 复方痤疮微乳膏及制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2006100440011A CN100446773C (zh) | 2006-04-29 | 2006-04-29 | 复方痤疮微乳膏及制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1879603A CN1879603A (zh) | 2006-12-20 |
CN100446773C true CN100446773C (zh) | 2008-12-31 |
Family
ID=37518112
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2006100440011A Expired - Fee Related CN100446773C (zh) | 2006-04-29 | 2006-04-29 | 复方痤疮微乳膏及制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100446773C (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101972282B (zh) * | 2010-10-25 | 2013-12-25 | 河北康灵医药科技有限公司 | 一种用于中药微乳膏贴剂的制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1072843A (zh) * | 1991-10-16 | 1993-06-09 | 理查森-维克斯有限公司 | 凝胶型化妆品组合物 |
CN1285186A (zh) * | 1999-05-27 | 2001-02-28 | 强生消费者公司 | 新颖的局部用制剂 |
CN1294519A (zh) * | 1999-02-18 | 2001-05-09 | 英法马有限公司 | 含有促进活性成分吸收活性的化合物的药物组合物 |
CN1528326A (zh) * | 2003-09-29 | 2004-09-15 | 中国医学科学院皮肤病研究所 | 主治痤疮的复方外用药物 |
-
2006
- 2006-04-29 CN CNB2006100440011A patent/CN100446773C/zh not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1072843A (zh) * | 1991-10-16 | 1993-06-09 | 理查森-维克斯有限公司 | 凝胶型化妆品组合物 |
CN1294519A (zh) * | 1999-02-18 | 2001-05-09 | 英法马有限公司 | 含有促进活性成分吸收活性的化合物的药物组合物 |
CN1285186A (zh) * | 1999-05-27 | 2001-02-28 | 强生消费者公司 | 新颖的局部用制剂 |
CN1528326A (zh) * | 2003-09-29 | 2004-09-15 | 中国医学科学院皮肤病研究所 | 主治痤疮的复方外用药物 |
Also Published As
Publication number | Publication date |
---|---|
CN1879603A (zh) | 2006-12-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1895239B (zh) | 一种姜黄素制剂及其制备方法 | |
CN102697672A (zh) | 熊果苷多重乳液及其制备方法 | |
CN103239389A (zh) | 一种治疗先兆性流产的黄体酮缓释凝胶的制备方法 | |
CN104434620A (zh) | 一种祛痘组合物及其制备方法 | |
CN101396344A (zh) | 丹皮酚微乳制剂及其制备方法 | |
CN105496809A (zh) | 肉苁蓉苯乙醇总苷微乳凝胶剂及其制备方法 | |
CN111603395B (zh) | 一种含有层状液晶的美白保湿乳液及其制备方法 | |
CN101991689B (zh) | 一种治疗瘙痒性皮肤病的药物组合物 | |
CN101822638A (zh) | 二苯乙烯类化合物的纳米乳及其制备方法 | |
CN100446773C (zh) | 复方痤疮微乳膏及制备方法 | |
CN107595655A (zh) | 一种水杨酸的载药系统及其制备方法和应用 | |
CN101181638A (zh) | 女性表面涂敷用避孕剂 | |
CN108125947A (zh) | 一种生物相容微乳液为载体的二氢杨梅素药剂、制备方法及应用 | |
WO2024012291A1 (zh) | 提高生发活性物质药效的组合物及其制备方法 | |
CN102166254A (zh) | 一种水包油型留兰香油纳米乳及其制备方法 | |
CN105534898A (zh) | 肉苁蓉苯乙醇苷纳米乳及其制备方法 | |
CN101288682B (zh) | 一种含有鸦胆子油的微乳及其制备方法 | |
CN101108165A (zh) | 一种辣椒碱微乳及微乳凝胶 | |
CN105581935B (zh) | 紫檀芪亚微米脂质粒及其制备方法 | |
CN101933902A (zh) | 盐酸格拉司琼微乳凝胶剂及其制备方法 | |
CN1836664A (zh) | 葛根素自乳化微乳组合物及其制备方法 | |
CN114344177A (zh) | 一种富含芒果苷的w/o/w凝胶型乳液及其制备方法和应用 | |
CN1903187B (zh) | 含有局麻药的复方异丙酚注射剂及制备工艺 | |
CN106580812A (zh) | 清痘修护霜 | |
CN106214506A (zh) | 一种包裹福斯高林的多层脂质囊泡的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: THE 401 HOSPITAL, JINAN MILITARY AREA COMMAND OF P Free format text: FORMER OWNER: WANG JURONG Effective date: 20130729 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20130729 Address after: 266071 Shandong city of Qingdao province Minjiang City Road No. 22 Patentee after: No.401 Hospital, Jinan Military Region, PLA Address before: 266071 Department of pharmacy, PLA 401 hospital, Shandong, Qingdao Province, China Patentee before: Wang Jurong |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20081231 Termination date: 20150429 |
|
EXPY | Termination of patent right or utility model |